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inhibitor;
Protein tyrosine
kinasesMethods: The INPULSIS trials are replicate Phase III, randomized, double-blind, studies
comparing the efficacy and safety of nintedanib 150 mg twice daily with placebo in patients
with IPF. Eligible patients were aged 40 years with a diagnosis of IPF within 5 years before
randomization who had undergone a chest high-resolution computed tomography (HRCT) scan
within 1-year before screening, and who had a forced vital capacity (FVC) of 50% predicted
and a diffusing capacity for carbon monoxide of 30e79% predicted. Participants were random-
ized 3:2 to receive nintedanib or placebo for 52 weeks. The primary endpoint is the annual rate
of decline in FVC. The key secondary endpoints are change from baseline in the total score on
the St. George’s Respiratory Questionnaire (a measure of health-related quality of life) over 52
weeks and time to first acute exacerbation.
Results: Enrolment of 1066 patients in 24 countries was completed in September 2012. Results
will be reported in the first half of 2014.
Conclusion: The INPULSIS trials will determine the efficacy of nintedanib in patients with IPF,
including its impact on disease progression as defined by decline in FVC, acute exacerbations
and health-related quality of life. In addition, they will characterise the adverse event profile
of nintedanib in this patient population.
Trial registration: Registered at ClinicalTrials.gov (identifiers: NCT01335464 and
NCT01335477).
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive fibrosing interstitial pneumonia [1]. An
accurate diagnosis of IPF requires the exclusion of other
known causes of interstitial lung disease, the presence of a
specific radiological pattern of usual interstitial pneumonia
(UIP) determined by high-resolution computed tomography
(HRCT), or specific combinations of HRCT and histopatho-
logic patterns in patients who have undergone surgical lung
biopsy [1]. IPF is considered a rare disease [2]. In a retro-
spective cohort study conducted in the United States using
data from a large healthcare claims database spanning a 5-
year period, the prevalence of IPF was estimated to be 14
to 43 cases per 100,000, and the annual incidence to be 6.8
to 16.3 per 100,000, depending on how cases were defined
[3]. Similarly, in the United Kingdom, the annual incidence
of IPF was estimated to be 7.4 per 100,000 based on pri-
mary care data from 2000 to 2008 [4]. IPF is ultimately a
fatal disease, with a reported median survival time of
approximately 3 years from diagnosis [5]. In addition, the
symptoms of IPF impact negatively on patients’ physical
function and emotional well-being, as well as their health-
related quality of life (HRQoL) [6,7].
An improved understanding of the pathogenic mecha-
nisms underlying IPF over the last decade has resulted in
several agents being evaluated in clinical trials [8] and in
pirfenidone being approved for the treatment of a subgroup
of patients with IPF in several countries. Results of four
large randomized, double-blind, placebo-controlled Phase
III trials investigating the efficacy and safety of treatments
for IPF are awaited this year: the PANTHER-IPF trial of N-
acetylcysteine (NAC) (NCT00650091), the ASCEND trial of
pirfenidone (NCT01366209), and the INPULSIS trials of
nintedanib (NCT01335464 and NCT01335477).
Nintedanib (formerly known as BIBF 1120) is a potent
tyrosine kinase inhibitor targeting intracellular receptors of
fibroblast growth factor receptor (FGFR), platelet-derivedgrowth factor receptor (PDGFR), and vascular endothelial
growth factor receptor (VEGFR) [9]. Activation of these
receptor kinases has been implicated in multiple pathways
in the pathogenesis of IPF [10,11]. In vitro studies and an-
imal models suggest that nintedanib has anti-fibrotic and
anti-inflammatory effects that may attenuate the progres-
sion of fibrosis [12,13]. Results from the Phase II
TOMORROW trial suggested that 12 months’ treatment with
nintedanib 150 mg twice daily results in a reduced rate of
decline in forced vital capacity (FVC), fewer acute exac-
erbations and preservation of HRQoL, measured using the
St. George’s Respiratory Questionnaire (SGRQ) [14]. The
purpose of this manuscript is to describe the design of the
INPULSIS studies, two replicate Phase III trials that further
investigate the efficacy and safety of nintedanib 150 mg
twice daily compared with placebo in patients with IPF.Methods
Trial design
Both the INPULSIS trials are multinational, randomized,
double-blind, parallel-group studies comparing the efficacy
and safety of nintedanib 150 mg twice daily with placebo in
patients with IPF. The INPULSIS trials were initiated in
May 2011 and enrolment (n Z 1066) was completed in
September 2012. Patients were recruited in 24 countries in
the Americas, Europe, Asia and Australia. Following a
screening period, eligible patients were randomized 3:2
(using an interactive phone/web response system) to
receive nintedanib or placebo for 52 weeks (Fig. 1). Each
study concluded with a 4-week follow-up period after
completion of the 52-week treatment period. A 3:2 ratio
was chosen to aid enrolment. In order to reduce the amount
of missing data, patients who discontinued trial drug, for
any reason, prior to completing the 52 weeks’ treatment
were asked to attend all visits and undergo all examinations
Figure 1 INPULSIS trial design. R, randomization (3:2 ratio for nintedanib:placebo); EOT, end of treatment; FU, follow-up. FVC
was measured at all visits except visits 6a, 7a and 8a, which were for blood sampling for laboratory tests only.
Table 1 Diagnostic criteria for IPF based on chest HRCT if
surgical lung biopsy was not available. To qualify for a
diagnosis of IPF if a surgical lung biopsy was not available,
the criteria A and B and C; or criteria A and C; or criteria B
and C had to be met.
A Definite honeycomb lung destruction with
basal and peripheral predominance
B Presence of reticular abnormality and
traction bronchiectasis consistent with fibrosis
with basal and peripheral predominance
C Atypical features are absent, specifically nodules and
consolidation. Ground glass opacity, if present, is less
extensive than reticular opacity pattern
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was to be collected for all patients who prematurely dis-
continued but did not agree to attend all visits until week
52.
For each trial, the sample size was calculated to provide
90% power to detect a difference of 100 mL/year between
the treatment groups in the rate of FVC decline. Based on
the Phase II TOMORROW trial data, the common standard
deviation for change from baseline in FVC was assumed to
be 300 mL. Assuming data from 2% of patients would be
non-evaluable, the sample size was calculated as 194 pa-
tients in the placebo group and 291 patients in the ninte-
danib 150 mg twice daily group if using a 2 group t-test at a
1-sided 2.5% level. Since the primary analysis is a random
coefficient regression model, including adjustment for
several variables and taking into account information
across time rather than at a single time-point, it is ex-
pected that the power will be greater than the 90% calcu-
lated for the t-test.
As in the Phase II TOMORROW trial, dose interruption
and/or reduction of the dose from 150 mg twice daily to
100 mg twice daily was allowed for the management of
adverse events. After an adverse event had resolved, the
dose could be reinstituted at 150 mg twice daily. The in-
vestigators were provided with guidelines on the manage-
ment of diarrhoea, a known side-effect related to
treatment with tyrosine kinase inhibitors [15,16]. Guide-
lines on the management of liver enzyme elevations were
also provided to the investigators. Patients who completed
the 52-week treatment period and the 4-week follow-up
period in the INPULSIS trials were invited to participate
in an open-label extension trial (NCT01619085).
Trial organisation and oversight
The INPULSIS trials were guided by an advisory committee
consisting of clinical experts in IPF and representatives of
the sponsor, Boehringer Ingelheim. An independent Data
Monitoring Committee (DMC) regularly reviewed the data,
in particular serious adverse events, adverse events leading
to discontinuation of study drug, and laboratory parame-
ters, and made recommendations to the sponsor about the
continuation of the trials. An Adjudication Committee
reviewed medical documentation for all deaths to evaluate
the primary cause of death in a blinded manner. Thiscommittee also adjudicated all events reported by the in-
vestigators as meeting the criteria for an acute exacerba-
tion of IPF as defined in the protocol, classifying them as a
confirmed acute exacerbation, suspected acute exacerba-
tion, or not an acute exacerbation.
Both trials were conducted in accordance with the
principles of the Declaration of Helsinki and the Harmo-
nized Tripartite Guideline for Good Clinical Practice from
the International Conference on Harmonization and were
approved by local authorities. The clinical trial protocol
was approved by an Independent Ethics Committee and/or
Institutional Review Board at all the participating centres.
All patients provided written informed consent prior to
study entry.Patients
To be eligible to participate in the INPULSIS trials, pa-
tients had to be 40 years of age with a diagnosis of IPF
established within 5 years before randomization, to have
undergone chest HRCT within 12 months before screening,
and to have an FVC 50% of predicted value [17] and a
carbon monoxide diffusion capacity (DLCO) of 30e79% of
predicted value [18]. The diagnosis of IPF was established
based on the central review of chest HRCT scans from all
patients by an expert radiologist (DMH) according to
protocol-specified criteria (Table 1). Surgical lung biopsy
specimens were also centrally evaluated if available by an
expert pathologist (AGN).
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transaminases or bilirubin above 1.5-fold upper limit of
normal), cardiac disease (i.e. myocardial infarction within
6 months or unstable angina within 1 month of randomi-
zation), or who, in the opinion of the investigator, were
likely to receive a lung transplant during the study were not
permitted to enter the trial. Patients who were taking full-
dose anticoagulant therapy or high-dose antiplatelet ther-
apy at screening, or had received treatment with NAC or
prednisone >15 mg/day or equivalent within 2 weeks of
screening, or pirfenidone, azathioprine, cyclophospha-
mide, cyclosporine A or any investigational drug within 8
weeks of screening, were excluded. Concomitant therapy
with prednisone 15 mg/day or equivalent was permitted if
the dose had been stable for 8 weeks prior to screening.
Patients who experienced deterioration, as judged by the
investigator, were permitted to receive concomitant
treatment with azathioprine, cyclophosphamide, cyclo-
sporine A, NAC, or prednisone >15 mg/day or equivalent at
the discretion of the investigator 6 months or more after
starting to receive study medication. In cases of acute
exacerbation, any treatments could be freely initiated or
increased as deemed appropriate by the investigator.
However, pirfenidone and any investigational treatments
for IPF were not allowed throughout the trial.
Outcome measures
The primary endpoint for the INPULSIS trials is the annual
rate of decline in FVC (mL/year), calculated from mea-
surements obtained over the 52 weeks of treatment
(Fig. 2). Spirometry testing was conducted according to
ATS/ERS criteria, including daily calibration of the spirom-
eter, regular calibration of the calibration pump and FVC
tests conducted in triplicate, with the highest result
selected [19]. All spirometry was performed on sponsor-
provided machines and ongoing feedback and training
were provided.Figure 2 Methodology for calculating slope of FVC decline. The
regression (random slopes and intercepts) model, including gender,
24, 36 and 52 weeks after randomization. All available FVC values
analysis except for patients who prematurely discontinue trial medi
be used.The key secondary endpoints are change from baseline
in SGRQ total score over 52 weeks and time to first acute
exacerbation. Acute exacerbations were defined as events
meeting all of the following criteria: unexplained worsening
or development of dyspnoea within 30 days, new diffuse
pulmonary infiltrates on chest X-ray and/or HRCT, or
parenchymal abnormalities with no pneumothorax or
pleural effusion (new ground-glass opacities) since last
visit. Causes of the acute worsening, including infection,
left heart failure, pulmonary embolism or any identifiable
cause of acute lung injury were to be excluded as per
routine clinical practice and microbiological studies.
Investigator-reported exacerbations were adjudicated by
the Adjudication Committee. Other secondary endpoints
include absolute changes from baseline in FVC (mL and %
predicted); proportion of FVC responders (patients who did
not have an absolute decline in FVC % predicted of >5% or
>10%); risk of an acute exacerbation; change from baseline
in SpO2 (oxygen saturation) at rest; change from baseline in
DLCO at rest (measured in accordance with ATS/ERS
guidelines [20]); all-cause, respiratory, and ‘on-treatment’
time to death. Composite endpoints of time to death or
lung transplant, and time to death or lung transplant or
meeting arbitrary pre-defined criteria for lung transplant
(FVC <45% predicted or DLCO <30% predicted or SpO2 <88%
at rest) were also included in order to capture a range of
outcomes indicating an unfavourable clinical course.
Further patient-reported outcomes (PROs) investigated
in the INPULSIS trials are the change from baseline to
week 52 in the score on the three SGRQ domains (impact,
symptoms, activity) [21], SGRQ-I [22], University of Cali-
fornia San Diego Shortness of Breath Questionnaire [UCSD-
SOBQ] [23], EuroQol 5-dimensional quality of life ques-
tionnaire [EQ5D], Cough and Sputum Assessment Ques-
tionnaire cough domains [CASA-Q(CD)] [24]; the proportion
of 4-point responders on SGRQ total score; and the pro-
portion of responders on Patient’s Global Impression of
Change (PGI-C). Safety assessment will include reporting ofprimary endpoint will be analysed using a random coefficient
age and height as covariates. Visits are planned at 2, 4, 6, 12,
except the value from the follow-up visit will be used in this
cation, in which case the value from the follow-up visit will also
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nation and weight; clinical laboratory tests (haematology,
clinical chemistry and urinalysis).Statistical analysis
Efficacy and safety analyses will be conducted on patients
who were randomized to treatment (nintedanib or placebo)
and received 1 dose of study medication. The annual rate
of decline in FVC will be primarily analysed using a random
coefficient regression (random slopes and intercepts)
model including gender, age and height as covariates. All
available FVC values from baseline to week 52 will be used
in the primary model, including FVC measurements from
the follow-up visit for patients who prematurely dis-
continued trial medication and did not complete study
visits until week 52. A linear model was chosen as in this
patient population, FVC is expected to decline linearly over
time. However, a number of alternative and sensitivity
analyses have been pre-specified in the statistical analysis
plan, such as change from baseline to week 52 in FVC and
other functional forms for the rate of decline (quadratic
and exponential) to assess the robustness of the linear
model. Model assumptions also include a normal distribu-
tion for the intercepts and slopes with an arbitrary
covariance matrix. An unstructured variance-covariance
structure will be used to model within-patient measure-
ments. The variance-covariance matrix, modeled to esti-
mate the inter-individual variability, will be considered to
have a Variance-Components structure. The Roger-Kenward
approximation will be used to estimate denominators de-
grees of freedom.
Change from baseline in SGRQ total score over 52 weeks
will be primarily analysed using mixed model repeated
measures (MMRM) with treatment and visit as fixed effects,
baseline SGRQ total score as a covariate, and treatment-by-
visit and baseline-by-visit as interaction terms. The patient
effect will be assumed to be random and compound sym-
metry covariance structure will be assumed for within-
patient variation.
KaplaneMeier estimates will be derived for the proba-
bility of a first acute exacerbation over time, and time to
first acute exacerbation will be primarily analysed using the
log rank test. The hazard ratios and their confidence in-
tervals will be computed using a Cox proportional hazards
model adjusted for gender, age and height. These cova-
riates were chosen in order to be consistent with the ana-
lyses performed in the Phase II TOMORROW trial [14] and
are the same covariates as included in the primary endpoint
model. The key secondary endpoint uses data on acute
exacerbations as reported by the site investigators, in
keeping with the Phase II methodology. Events adjudicated
as confirmed or suspected acute exacerbations by the
Adjudication Committee will be assessed in a sensitivity
analysis of data pooled from both INPULSIS trials.
A hierarchical procedure will be used to demonstrate
the superiority of nintedanib over placebo for the primary
and key secondary endpoints. The consecutive steps of the
hierarchy will only be considered if the previous step is
significant at the 1-sided 2.5% level and the results are in
favour of nintedanib. Two hierarchies of endpoints, with adifferent order of the key secondary endpoints for sub-
missions to US and EU/rest of world regulatory authorities,
will be tested. For the US submission, time to first acute
exacerbation is the first key secondary endpoint; for the
EU/rest of world submissions, change from baseline in SGRQ
total score over 52 weeks is the first key secondary
endpoint. No hierarchy will be used for the other secondary
endpoints.
Absolute and relative changes from baseline in FVC over
52 weeks will be analysed using MMRM, with treatment and
visit as fixed effects and baseline value, gender, age and
height as covariates, and treatment-by-visit and baseline-
by-visit as interaction terms. Changes in other respiratory
parameters will be analysed in the same way as change in
FVC. Changes in other PROs will be analysed in the same
way as change in SGRQ total score.
For the survival analyses, a log rank test will be used to
compare treatment groups and a Cox model adjusted for
gender, age and height will be used to determine hazard
ratios. These covariates were chosen in order to be
consistent with the analyses performed in the Phase II
TOMORROW trial [14] and are the same covariates as
included in the primary endpoint model. Since the number
of deaths is expected to be low, the protocol specified that
survival analyses will additionally be performed on the
pooled data from both INPULSIS trials. Safety analyses will
be descriptive.
Sensitivity analyses will be performed to assess the
robustness of the results of the primary and key secondary
endpoints. Model assumptions will be checked and sensi-
tivity to data handling, including missing data handling, will
be assessed. In order to improve the precision of the
treatment effect estimates for the efficacy endpoints and
to increase the size of the safety database, a pooled
analysis of the two trials was pre-specified as an additional
supportive analysis.
Discussion
Rationale for dose selection
The dose of nintedanib used in the INPULSIS trials was
selected based on findings from the 12-month Phase II
TOMORROW study [14]. In the TOMORROW trial, the annual
rate of decline in FVC in the nintedanib 150 mg twice daily
group was 0.06 L (95% CI, 0.14 to 0.02) compared with
0.19 L (95% CI, 0.26 to 0.12) in the placebo group: a
difference of 0.13 L (95% CI, 0.03e0.24). In addition,
treatment with nintedanib 150 mg twice daily was associ-
ated with preservation of HRQoL (mean change in SGRQ
total score of 0.66 [95% CI, 4.02 to 2.71] versus 5.46 [95%
CI, 2.06, 8.86] with placebo: a difference of 6.12 [95% CI,
10.57 to 1.67]) and a reduction in the risk of acute ex-
acerbations (risk ratio compared with placebo: 0.16 [95%
CI, 0.03 to 0.70]).
Rationale for endpoints
The most robust primary endpoint for Phase III clinical trials
in IPF is all-cause mortality [25]. However, the mortality
rate of patients enrolled in the TOMORROW trial was low,
1028 L. Richeldi et al.and it was assessed that it was not feasible to use mortality
as the primary endpoint in the INPULSIS trials. Based on
the 1-year survival rates observed in the TOMORROW study
(89.2% of patients in the placebo group and 91.7% of pa-
tients in the nintedanib 150 mg twice daily group) it was
calculated that a 1-year trial would require the inclusion of
a total of approximately 6000 patients to provide 90%
power to detect a difference between groups with a 2-sided
p-value of 5%.
In the absence of an alternative explanation, a decrease
in FVC in patients with IPF is consistent with progressive
disease [1] and has been shown to be associated with
reduced survival time in patients with IPF [26e32]. Change
in FVC over 1 year has been used as a primary endpoint for
Phase III clinical trials in patients with IPF [25,33]. The
annual rate of decline in FVC e the primary endpoint in the
INPULSIS trials e uses all the FVC values collected during
the trial. This was considered to be a more robust meth-
odology than using only the FVC value from baseline and 52
weeks because it enables calculation of the rate of decline
even in patients without a week 52 value.
Several PROs for the assessment of the symptoms of IPF
and the broader construct of HRQoL have been included as
secondary endpoints in the INPULSIS trials. The SGRQ,
chosen as a key secondary endpoint in the INPULSIS trials,
has demonstrated acceptable psychometric characteristics
in patients with IPF, including construct validity, reliability,
and ability to detect change over time [22,34e36]. The two
PROs used to assess dyspnoea, the UCSD-SOBQ and CASA-Q
(CD), have been shown to have content validity in patients
with IPF [37], with the UCSD-SOBQ also shown to detect
change over time [36,38].
In the INPULSIS trials, acute exacerbations reported by
the investigators will be assessed as a key secondary
endpoint, as was done in the Phase II TOMORROW trial, in
which a clinically relevant efficacy signal on acute exac-
erbations was observed. Furthermore, recent data suggest
that suspected acute exacerbations (events that the
investigator thinks are acute exacerbations but that cannot
be adjudicated as acute exacerbations due to missing data
or criteria) are clinically indistinguishable from confirmed
acute exacerbations defined according to the consensus
diagnostic criteria [39] and that both are clinically mean-
ingful events [40]. Investigator-identified acute exacerba-
tions were felt to best capture both definite and suspected
acute exacerbations.Conclusions
The INPULSIS trials will investigate the efficacy of nin-
tedanib in patients with IPF, including its impact on dis-
ease progression as defined by decline in FVC, acute
exacerbations and HRQoL. In addition, the data collected
will characterise the adverse event profile of nintedanib
in this patient population. The INPULSIS trials will
report results in the first half of 2014. Together with the
results of the other large ongoing randomized placebo-
controlled trials in IPF, the INPULSIS trials will add
significantly to scientific understanding of the natural
history of IPF and will have potential implications for
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